{"organizations": [], "uuid": "382c4550dfa005198742b51ad08b50a3b10f014e", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/johnsonjohnson-patent-remicade/update-1-u-s-appeals-court-upholds-ruling-invalidating-jj-patent-on-remicade-idUSL2N1PI12X", "country": "US", "domain_rank": 408, "title": "UPDATE 1-U.S. appeals court upholds ruling invalidating J&J patent on Remicade", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-23T18:14:00.000+02:00", "replies_count": 0, "uuid": "382c4550dfa005198742b51ad08b50a3b10f014e"}, "author": "", "url": "https://www.reuters.com/article/johnsonjohnson-patent-remicade/update-1-u-s-appeals-court-upholds-ruling-invalidating-jj-patent-on-remicade-idUSL2N1PI12X", "ord_in_thread": 0, "title": "UPDATE 1-U.S. appeals court upholds ruling invalidating J&J patent on Remicade", "locations": [], "entities": {"persons": [{"name": "jan wolfe", "sentiment": "none"}], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "j&j", "sentiment": "negative"}, {"name": "johnson & johnson", "sentiment": "none"}, {"name": "pfizer", "sentiment": "none"}, {"name": "u.s. circuit court of appeals for the federal circuit", "sentiment": "none"}, {"name": "pfizer inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 16 PM / in 6 minutes UPDATE 1-U.S. appeals court upholds ruling invalidating J&J patent on Remicade Reuters Staff \n(Adds details) \nBy Jan Wolfe \nJan 23 (Reuters) - A U.S. appeals court on Tuesday upheld a ruling that invalidated a crucial Johnson & Johnson patent on its blockbuster rheumatoid arthritis drug Remicade, limiting J&J’s ability to seek damages from Pfizer Inc over its launch of a lower-cost version of the drug. \nThe U.S. Circuit Court of Appeals for the Federal Circuit affirmed a ruling by a U.S. administrative court that a J&J patent covering the active ingredient in Remicade was invalid because its concepts were covered in a prior J&J patent. \nRepresentatives of J&J and Pfizer did not immediately respond to requests for comment on the ruling. \nRemicade generated U.S. sales of $4.8 billion for J&J in 2016 but faces increased competition from cheaper “biosimilar” copycats, including Pfizer’s version, which is sold in the U.S. under the name Inflectra. \nPfizer launched Inflectra in October 2016 after winning a set of rulings that invalidated J&J’s patent. \nJ&J said at the time that it considered Pfizer’s maneuver to be an “at risk” launch, meaning Pfizer would be liable for money damages to J&J if an appeals court reversed the rulings and upheld the patent. (Reporting by Jan Wolfe; Editing by Bernadette Baum)", "external_links": [], "published": "2018-01-23T18:14:00.000+02:00", "crawled": "2018-01-23T18:28:32.009+02:00", "highlightTitle": ""}